Hydrocortisone Dosage for IBD Active Flares
For severe active IBD flares requiring hospitalization, use intravenous hydrocortisone 400 mg/day (100 mg every 6 hours) or methylprednisolone 60 mg/day, with treatment duration limited to 48-72 hours before transitioning to oral corticosteroids or escalating to rescue therapy if no response. For moderate flares managed as outpatients, oral prednisolone 40 mg daily is the standard approach, not hydrocortisone.
Adult Dosing by Disease Severity
Severe Disease (Hospitalized Patients)
Intravenous hydrocortisone 400 mg/day is the established dose for acute severe ulcerative colitis and severe Crohn's disease 1. This is typically administered as 100 mg every 6 hours. The FDA label confirms the initial dose range of 100-500 mg depending on disease severity, with repeat dosing at 2,4, or 6-hour intervals 2.
Alternative: Methylprednisolone 60 mg/day IV is equally effective 1. Recent AGA guidelines suggest using methylprednisolone doses equivalent to 40-60 mg/day rather than higher doses, as meta-regression analysis showed no correlation between higher corticosteroid doses and reduced colectomy rates 3.
Critical timing consideration: High-dose IV corticosteroid therapy should be continued only until the patient stabilizes, typically not beyond 48-72 hours 2. If hydrocortisone therapy must continue beyond 48-72 hours, consider switching to methylprednisolone due to hydrocortisone's stronger mineralocorticoid effects and risk of hypernatremia 2.
Moderate Disease (Outpatient Management)
Oral prednisolone 40 mg daily is the appropriate corticosteroid for moderate disease, NOT hydrocortisone 4, 1, 5. The 2019 British Society of Gastroenterology guidelines strongly recommend prednisolone 40 mg daily with weaning over 6-8 weeks for moderate to severe ulcerative colitis 4. This same dose applies to Crohn's disease 1.
The 40 mg dose is based on evidence showing it is more effective than 20 mg/day, with no additional benefit from doses above 40-60 mg/day and increased adverse effects at higher doses 4, 5.
Pediatric Dosing
For children, the initial hydrocortisone dose ranges from 0.56 to 8 mg/kg/day in three or four divided doses (equivalent to 20-240 mg/m²/day) 2. The wide range reflects the need to tailor dosing based on the specific disease entity and severity.
For moderate disease in children, consider enteral nutrition as an alternative to corticosteroids, particularly when there are concerns about growth or side effects 6.
Key Clinical Decision Points
When to Use IV vs. Oral Corticosteroids
- IV hydrocortisone/methylprednisolone: Patients meeting Truelove and Witts criteria for severe disease (≥6 bloody stools/day plus fever >37.8°C, tachycardia >90 bpm, anemia <10.5 g/dL, or ESR >30 mm/hr), or those with systemic symptoms requiring hospitalization
- Oral prednisolone: Moderate disease without systemic symptoms, outpatient management
Response Assessment and Treatment Duration
Patients should show improvement within 2 weeks of oral prednisolone 4. If no response after 2 weeks, consider treatment escalation to biologics or hospital admission depending on systemic illness severity 4.
For hospitalized patients on IV corticosteroids, assess response at 3-5 days. Continued use beyond 7 days has not been shown effective in non-responders 3. The typical colectomy risk is 25-30% despite optimal medical management 1.
Tapering Strategy
Prednisolone should be reduced gradually over 6-8 weeks 4, 1. More rapid reduction is associated with early relapse 1. Single daily dosing is as effective as split-dosing and causes less adrenal suppression 4.
Important Caveats
Hydrocortisone vs. Methylprednisolone: A 2021 comparative study found that IV methylprednisolone resulted in significantly more requirement for rescue therapy (36.4% vs 19.6%) compared to hydrocortisone, though it caused less hypokalemia 7. However, this contradicts the guideline-recommended equivalence. The clinical significance of the hypokalemia difference was negligible in practice 7.
Prior steroid exposure matters: Historical data suggests that in ulcerative colitis, patients without prior steroid exposure may respond better to ACTH/corticotropin, while those already on steroids may respond better to hydrocortisone 8. However, this distinction is not reflected in current guidelines and ACTH is rarely used in modern practice.
Avoid prolonged use: Approximately 50% of patients experience short-term corticosteroid-related adverse events including acne, edema, sleep and mood disturbance, glucose intolerance, and dyspepsia 4. Corticosteroids have no role in maintenance therapy for either ulcerative colitis or Crohn's disease 1.
Steroid-sparing strategy: Patients requiring two or more corticosteroid courses within a calendar year, those who relapse as prednisolone is reduced below 15 mg, or those who relapse within 6 weeks of stopping steroids should be escalated to thiopurines, anti-TNF therapy, vedolizumab, or tofacitinib 4, 1.